wot power leveling - ESF

Medical: the strength of apparent stagnation medical: the company is mainly engaged in research and development, production and sales of percutaneous coronary intervention medical equipment. Is the high-end medical equipment capable of forming strong competition with foreign products in the area of one of the smaller enterprises. Our main products include intravascular drug used in treatment of coronary heart disease (Sirolimus)-eluting stent system and shootArtery stent delivery system, PTCA balloon catheters, drug such as central venous catheter. Main products of the company's subsidiary Shanghai shape for closure of patent ductus arteriosus (PDA) blocking devices, atrial septal defect (ASD) block, Ventricular septal defect (VSD) Occluder; holding subsidiary and main classes involved in medical products for anesthesia, cardiac intervention operationWith sheath and wire; subsidiary of guardian Golden sails main products for the treatment of heart disease WINMEDIC 2000 angiography machine, and so on. Company's carrier-free drug-eluting stent is expected to grow at high speed. No carrier in drug-eluting stent in patients with higher security requirements with unique, irreplaceable role, such as short-term needs surgery in some patients, the use of carrier drug-eluting stentNeed long-term taking of blood coagulation drugs, surgery may not be possible. So the company first on the security requirements of better promoting carrier-free drug-eluting stent in patients with. Of drug-eluting stent with no carrier is expected to gradually promote, share of the revenue of company support in the future will be more and more high. Mergers and acquisitions overseas dealers Comed company. According to the company, Comed companyIs a company specializing in cardiovascular interventional and surgical medical equipment sales distributors, sales channels covering Europe, North America, the Middle East, Latin America and other countries. From now, 10 Comed company turnover of EUR 7.8 million world of tanks power leveling, its rapid revenue growth, sales revenue of nearly six years an average annual compound growth rate of 28.3%. Merging ComedCompany helps companies expand overseas market, brand and product certification faster. Company has passed the certification of the variety can be made directly through Comed's channel sales and broaden sales market, make rapid breakthroughs in overseas sales. Taking into account the cultural, differences such as management, the acquisition of the company relatively cautious, to make and to increase capital access to Comed70% stake in the company. It Comed stability played an important role in the development of the company. In addition, the company's research and development capabilities in an industry-leading position, the company accumulated powerful development force wot power leveling, carrier-free drug-eluting stent development and approval is the best example. Now research products primarily in the support systems and heart valve. specific research products may be listedFollowed by: 2013 two-drug, antibody scaffolds; December 2014 fully biodegradable scaffold (magnesium stent, polymer degradation of stents); 2014 left atrial appendage occlusion June 2015 transcatheter valve (bio-valve: through the femoral artery enters. Without the need for open-chest). On the secondary market, which after early shock risk after adjustment has been released�� But in February and small-cap stocks have rebounded amid company shares are not active, belong to the evident stagnation unit. Established rebounded as the market trends, shares rose strongly complement requirements world of tanks power leveling, expected future still is expected to amount to meet up again, it is recommended that investors pay due attention. var selfURL="http://quotes.cnfol.com/block/7039"; Online statement Gold: gold online reprint of the above content, does not indicate that confirm the description, for investors ' reference only and does not constitute investment advice. Investor operations accordingly, at your own risk.